- Home
- ZYME vs BANR Comparison
ZYME vs BANR Comparison
Compare ZYME & BANR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZYME | BANR |
|---|---|---|
| Founded | 2003 | 1890 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.2B |
| IPO Year | 2022 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ZYME | BANR |
|---|---|---|
| Price | $22.88 | $59.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | $38.90 | ★ $71.20 |
| AVG Volume (30 Days) | ★ 630.3K | 316.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.37% |
| EPS Growth | ★ 33.33 | 15.57 |
| EPS | N/A | ★ 5.64 |
| Revenue | ★ $105,965,000.00 | N/A |
| Revenue This Year | $162.82 | $0.73 |
| Revenue Next Year | N/A | $5.69 |
| P/E Ratio | ★ N/A | $10.52 |
| Revenue Growth | ★ 38.87 | N/A |
| 52 Week Low | $9.03 | $54.01 |
| 52 Week High | $28.49 | $69.83 |
Technical Indicators
Market Signals| Indicator | ZYME | BANR |
|---|---|---|
| Relative Strength Index (RSI) | 43.81 | 37.53 |
| Support Level | $22.23 | N/A |
| Resistance Level | $23.66 | $64.67 |
| Average True Range (ATR) | 1.42 | 1.88 |
| MACD | -0.05 | -0.16 |
| Stochastic Oscillator | 9.06 | 31.84 |
Price Performance
Historical ComparisonAbout ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About BANR Banner Corporation
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.